“…NEO100 (NeOnc Technologies, Inc., Los Angeles, CA, USA) is an ultra-pure, pharmaceutical-grade version of perillyl alcohol, a naturally occurring monoterpenoid that is present, for example, in the essential oils of citrus fruit peel as a metabolite of limonene. Like perillyl alcohol [ 13 ], NEO100 has been extensively investigated for its cancer therapeutic potential, and recently published results from a Phase 1 trial applying intranasal delivery of NEO100 to recurrent glioblastoma patients showed exceptional safety and encouraging signs of activity [ 14 , 15 ]. Independent from these intranasal studies that focused on NEO100’s potential as a cancer therapeutic, Wang et al pursued the question whether IA injection of NEO100 would result in BBB opening in a manner that is safe and reversible, and potentially useful to enable beneficial brain entry of otherwise low-BBB-permeable therapeutics, such as methotrexate and therapeutic antibodies.…”